These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 12463442)
21. The economic burden of the ankylosing spondylitis in the Czech Republic: comparison between 2005 and 2008. Petříková A; Doležal T; Klimeš J; Vocelka M; Sedová L; Kolář J Rheumatol Int; 2013 Jul; 33(7):1813-9. PubMed ID: 23314983 [TBL] [Abstract][Full Text] [Related]
22. Costs and quality of life of patients with ankylosing spondylitis in Canada. Kobelt G; Andlin-Sobocki P; Maksymowych WP J Rheumatol; 2006 Feb; 33(2):289-95. PubMed ID: 16465660 [TBL] [Abstract][Full Text] [Related]
23. The Cost of Ankylosing Spondylitis in the UK Using Linked Routine and Patient-Reported Survey Data. Cooksey R; Husain MJ; Brophy S; Davies H; Rahman MA; Atkinson MD; Phillips CJ; Siebert S PLoS One; 2015; 10(7):e0126105. PubMed ID: 26185984 [TBL] [Abstract][Full Text] [Related]
24. The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade). Kobelt G; Andlin-Sobocki P; Brophy S; Jönsson L; Calin A; Braun J Rheumatology (Oxford); 2004 Sep; 43(9):1158-66. PubMed ID: 15226514 [TBL] [Abstract][Full Text] [Related]
25. Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries. Boonen A; van der Heijde D; Landewé R; Guillemin F; Rutten-van Mölken M; Dougados M; Mielants H; de Vlam K; van der Tempel H; Boesen S; Spoorenberg A; Schouten H; van der Linden S Ann Rheum Dis; 2003 Aug; 62(8):732-40. PubMed ID: 12860728 [TBL] [Abstract][Full Text] [Related]
26. A systematic literature review of the economic impact of ankylosing spondylitis. Palla I; Trieste L; Tani C; Talarico R; Cortesi PA; Mosca M; Turchetti G Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S136-41. PubMed ID: 23072824 [TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of TNF-α inhibition in active ankylosing spondylitis: a systematic appraisal of the literature. Kirchhoff TD; Mittendorf T; Schmidt RE; Jablonka A; Merkesdal S Expert Rev Pharmacoecon Outcomes Res; 2012 Jun; 12(3):307-17. PubMed ID: 22812555 [TBL] [Abstract][Full Text] [Related]
28. The direct healthcare costs associated with ankylosing spondylitis patients attending a UK secondary care rheumatology unit. Ara RM; Packham JC; Haywood KL Rheumatology (Oxford); 2008 Jan; 47(1):68-71. PubMed ID: 18077492 [TBL] [Abstract][Full Text] [Related]
29. Costs and quality of life of patients with ankylosing spondylitis in Hong Kong. Zhu TY; Tam LS; Lee VW; Hwang WW; Li TK; Lee KK; Li EK Rheumatology (Oxford); 2008 Sep; 47(9):1422-5. PubMed ID: 18635597 [TBL] [Abstract][Full Text] [Related]
30. Functional disability predicts total costs in patients with ankylosing spondylitis. Ward MM Arthritis Rheum; 2002 Jan; 46(1):223-31. PubMed ID: 11817595 [TBL] [Abstract][Full Text] [Related]
31. [Costs and benefits of an education program for patients with ankylosing spondylitis as part of an inpatient rehabilitation programs-study design and first results]. Krauth C; Rieger J; Bönisch A; Ehlebracht-König I Z Rheumatol; 2003; 62(Suppl 2):II14-6. PubMed ID: 14648082 [TBL] [Abstract][Full Text] [Related]
32. The indirect costs of ankylosing spondylitis: a systematic review and meta-analysis. Malinowski KP; Kawalec P Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):285-300. PubMed ID: 25579502 [TBL] [Abstract][Full Text] [Related]
33. Costs of ankylosing spondylitis in three European countries: the patient's perspective. Boonen A; van der Heijde D; Landewé R; Guillemin F; Spoorenberg A; Schouten H; Rutten-van Mölken M; Dougados M; Mielants H; de Vlam K; van der Tempel H; van der Linden S Ann Rheum Dis; 2003 Aug; 62(8):741-7. PubMed ID: 12860729 [TBL] [Abstract][Full Text] [Related]
34. Working life and physical activity in ankylosing spondylitis pre and post anti-tumor necrosis factor-alpha therapy. Prince DS; McGuigan LE; McGirr EE Int J Rheum Dis; 2014 Feb; 17(2):165-72. PubMed ID: 24576272 [TBL] [Abstract][Full Text] [Related]
35. The cost-effectiveness of infliximab (Remicade) in the treatment of ankylosing spondylitis in Canada. Kobelt G; Andlin-Sobocki P; Maksymowych WP J Rheumatol; 2006 Apr; 33(4):732-40. PubMed ID: 16583476 [TBL] [Abstract][Full Text] [Related]
36. Cost effectiveness of group physical therapy compared to individualized therapy for ankylosing spondylitis. A randomized controlled trial. Bakker C; Hidding A; van der Linden S; van Doorslaer E J Rheumatol; 1994 Feb; 21(2):264-8. PubMed ID: 8182635 [TBL] [Abstract][Full Text] [Related]
37. Societal costs of rheumatoid arthritis in Hong Kong: a prevalence-based cost-of-illness study. Zhu TY; Tam LS; Li EK Rheumatology (Oxford); 2011 Jul; 50(7):1293-301. PubMed ID: 21330341 [TBL] [Abstract][Full Text] [Related]
38. Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom. Botteman MF; Hay JW; Luo MP; Curry AS; Wong RL; van Hout BA Rheumatology (Oxford); 2007 Aug; 46(8):1320-8. PubMed ID: 17545684 [TBL] [Abstract][Full Text] [Related]
39. A discrete event modelling framework for simulation of long-term outcomes of sequential treatment strategies for ankylosing spondylitis. Tran-Duy A; Boonen A; van de Laar MA; Franke AC; Severens JL Ann Rheum Dis; 2011 Dec; 70(12):2111-8. PubMed ID: 21857027 [TBL] [Abstract][Full Text] [Related]
40. Direct and indirect costs associated with ankylosing spondylitis and related disease activity scores in Turkey. Akkoç N; Direskeneli H; Erdem H; Gül A; Kabasakal Y; Kiraz S; Balkan Tezer D; Hacıbedel B; Hamuryudan V Rheumatol Int; 2015 Sep; 35(9):1473-8. PubMed ID: 25749712 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]